Kornimate/medical-research-clean huggingface dataset:
utility of advanced ultrasound otoscope in the diagnosis of aom

Conditions: Otitis Media Recurrent; Middle Ear Infection; Ear Infection

Summary: the objective of this study is to collect ultrasound signal information and visual otoscopic images with an engineering prototype device for children scheduled for tympanostomy tube surgery for the purpose of algorithm development.

the objective of this study is to collect ultrasound signal information and visual otoscopic images with an engineering prototype device for children scheduled for tympanostomy tube surgery for the purpose of algorithm development. after informed consent from a parent or guardian is obtained, ultrasound and visual data will be collected for each of the child's ears. the images will be taken with the advanced ultrasound otoscope device. the ear laterality will be noted as well as any infection present in the fluid, non-infected fluid, or normal findings in the middle ear as reported by the surgeon. no identifiable data will be recorded. each study participant will be given a unique study number that will be linked to the images and middle ear findings. no additional information is gathered including age, sex, name or other phi. the images and corresponding study data will be stored on a password protected smartphone or tablet as well as on a password protected external hard drive. other characteristics that will be collected include surgical and lab findings regarding effusion, presence or absence (i.e. effusion). the middle ear fluid which is usually suctioned will be collected in a trap chamber- tympap- and this collected fluid will be sent to the microbiology laboratory for analysis investigators will be collecting ultrasound and visual data from the tympanic membrane. the images the investigators are collecting are optical images of the surface of the tympanic membrane. the waveforms do not traverse the body tissue, the tympanic membrane is a strong reflector, and the signal is returned to the ultrasound transducer for processing the waveform from an analog to a digital signal. the power of the ultrasound signal is 1/1000th of the ultrasound power used for fetal imaging which is considered safe.

Eligibility criteria:
inclusion criteria: * newborn to 12 years of age * receiving first set of pressure equalization (pe) tubes, even if coordinated with other procedures such as adenoidectomy * indication for surgery includes recurrent acute otitis media, chronic otitis media with effusion, eustachian tube dysfunction, and/or hearing loss. exclusion criteria: * cholesteatoma, tympanic membrane perforation, myringitis * history of pe tube placement or pe tubes currently in place.

Keywords: otoscope tympanogram effusion ultrasound
gene expression profile after gonadotropin releasing hormone (gnrh) agonist trigger of oocyte maturation

Conditions: Endometrial Receptivity; Ovarian Hyperstimulation Syndrome

Summary: the purpose of this study is to compare gene expression profiles in endometrial biopsies during the window of implantation after triggers of oocyte maturation using gnrh agonist or hcg and compared with their natural cycles in order to identify genes that may be dysregulated in gnrh agonist-triggered cycles. the investigators also intend to evaluate patients feeling of well being and physical quality of life after gnrh agonist trigger compared with hcg trigger.

ovarian hyperstimulation syndrome (ohss) is an iatrogenic complication of controlled ovarian hyperstimulation (coh) which may result in significant morbidity and rarely mortality as well as significant financial and psychological distress. the use of a gnrh agonist for induction of final oocyte maturation in ovarian stimulation cycles utilizing gnrh antagonist for pituitary suppression has proven to be an effective method of preventing the risk of ohss development. unfortunately, some studies, but not all, have also reported lower pregnancy rates in these cycles as compared to cycles using hcg trigger and this has been attributed to possible impaired endometrial receptivity. the investigators intend to obtain endometrial biopsies collected from the same subject in a natural cycle and then a biopsy during either a gnrh agonist or hcg triggered stimulation. expression profiles of mrnas will first be screened using microarray technology. relative levels of specific mrnas that display altered expression in the gnrh-triggered samples, as assayed by microarray, will then be confirmed by real-time, quantitative reverse transcription/polymerase chain reaction (q-pcr). the investigators shall also evaluate patients feeling of well being and physical quality of life after gnrh agonist trigger compared with hcg trigger.

Eligibility criteria:
inclusion criteria: * oocyte donors * ages between 21 and 33 * normal baseline serum fsh \< 10miu/ml exclusion criteria: * hypothalamic dysfunction * smokers * baseline serum fsh ≥ 10miu/ml

Keywords: gnrha trigger endometrial gene profile quality of life
study to compare different light therapies (narrowband ultraviolet b vs puva) for hand and foot skin diseases.

Conditions: Dermatitis; Psoriasis

Summary: hand and foot skin diseases, such as dermatitis and psoriasis, that do not respond to topical creams can be treated with ultraviolet light therapy. topical psoralen plus ultraviolet a (puva) is commonly used to treat these conditions, but requires additional time for the hands and feet to soak in psoralens before the light treatment. newer narrowband ultraviolet b (nbuvb) units have become available which allow for light treatment without soaking first. the purpose of this study is to determine if nbuvb is as effective as puva for hand and foot skin diseases.


Eligibility criteria:
inclusion criteria: bilateral hand or foot skin disease (dermatitis, psoriasis, etc.) with symmetric distribution and severity. exclusion criteria: age \<18 years pregnancy liver disease kidney disease history of skin cancer phototherapy or systemic therapy for the skin condition in the preceding 3 months
effects of amorphous calcium carbonate supplementation on bone health in postmenopausal women with osteopenia

Conditions: Calcium; Osteopenia; Bone Mineral Density; Bone Turnover Marker

Summary: this research was designed in accordance to the method for efficacy assessment of health food for bone heath. changes to bone density were measured to evaluate the effectiveness of amorphous calcium carbonate in maintaining bone health.

bone comprises organic matter, predominantly protein, and inorganic matter including various mineral salts. inappropriate nutrition profile can affect the balance of bone metabolism and cause bone loss. of all nutrients, calcium is considered the most important for bone structure and metabolism. it is the most common deficit that affects bone health. low dietary calcium intake can lead to negative calcium balance. low blood calcium (\< 10mg/dl) induces the release of parathyroid hormone (pth), which activates the conversion process of 25-(oh)-d3 to physiologically active 1,25-(oh)2-d3 in kidneys. pth and 1,25-(oh)2-d3 act jointly to change the ionic valence of hydroxyapatite, converting orthophosphate to pyrophosphate. this causes hydroxyapatite to easily dissociate and release calcium ion in order to compensate the blood calcium level. this is called bone resorption. while this physiological mechanism maintains blood calcium homeostasis, it also causes bone loss that can develop into osteoporosis. negative calcium balance is not only caused by lack of dietary calcium, hormonal abnormality or vitamin d deficit may also lead to negative calcium balance and the development of osteoporosis. this study aims to assess the effects of uic amorphous calcium on osteoporosis with "bone change test" and "calcium bioavailability test".

Eligibility criteria:
inclusion criteria: * menopausal women were recruited (those who had just started menopause or less than 10 years post-menopause were preferred). exclusion criteria: * respiratory insufficiency, * sleep apnea, * gastroesophageal reflux, * neurological or liver disease, * malignant tumor, alcohol abuse, * hysterectomy or hormonal therapy, * and depressive symptoms.
high- and low-dose radiotherapy combined with envafolimab for metastatic solid tumor

Conditions: Metastatic Cancer

Summary: the purpose of this study is to explore the efficacy and safety of high- and low-dose radiotherapy (hd-rt/ld-rt) combined with envafolimab (i) in the treatment of metastatic solid tumors that have failed first-line immunotherapy or above.


Eligibility criteria:
inclusion criteria: 1. patients with metastasis (including recurrence) solid tumors and failure with first-line or above immunotherapy (pd-1/pd-l1/ctla-4 inhibitors), and no subsequent standard treatment regimen. 2. previous histopathologic confirmation of malignancy. 3. tumor diameter \> 5 cm or the number of metastases is 6-15 (at least one measurable lesion, bone metastases are not used as target lesions), not suitable for conventional radiotherapy, surgery, radiofrequency ablation, and other treatments. 4. patients with an ecog score of 0 or 1, and an expected survival period of ≥6 months. 5. during the study, they are willing to follow the arrangement and not use other systemic anti-tumor drugs such as chemotherapy, targeted, chinese herbal medicine, and proprietary chinese medicine. 6. 18-70 years old, no gender limit. exclusion criteria: * 1. patients with glioma or brain metastases. 2. those with a history of severe immediate allergy to the drugs used in this study. 3. suffered from other malignant tumors other than nasopharyngeal carcinoma within 5 years (except for tumors with an expected 5-year os\>90%, such as non-melanoma skin cancer or pre-invasive cervical cancer). 4. cancer patients who require urgent surgical intervention, such as high-risk pathological fractures, life-threatening bleeding symptoms, etc. 5. any of the following conditions in the 6 months before screening: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient cerebral ischemia onset or symptomatic pulmonary embolism. patients with known coronary artery disease, congestive heart failure that does not meet the above criteria or left ventricular ejection fraction \<50% must adopt an optimized and stable medical plan determined by the treating doctor. if appropriate, you can consult a cardiologist. 6. received systemic anti-tumor therapy such as targeted therapy and biological drug therapy within 3 weeks before the first dose; have received any chinese herbal medicine or proprietary chinese medicine with anti-tumor indications within 7 days before the first dose.

Keywords: metastatic solid tumor immune checkpoint inhibitors radiotherapy objective response rate
catatonia in nodding syndrome and lorazepam treatment

Conditions: Catatonia; Nodding Syndrome

Summary: nodding syndrome is an enigmatic neuropsychiatric syndrome affecting children and adolescents mostly in eastern africa. the symptoms of nodding syndrome and catatonia seem to overlap. the researchers' objectives in this study were to investigate the presence and types of catatonic symptoms in children with nodding syndrome and observe their response to one or two doses of lorazepam, the first-line treatment for catatonia.

in this pilot study, the investigators examined a convenient sample of children and adolescents with nodding syndrome (ns) for catatonic symptoms using standardized criteria. the investigators also tested whether oral lorazepam (lzp) administered to those who qualified to have pediatric catatonia would alleviate symptoms. this was a cross-sectional descriptive study of catatonia in ns patients in northern uganda and an exploratory study of using one or two doses of lorazepam as a catatonia test. all the children with confirmed ns that had 2 or more of symptoms of catatonia were recruited to undergo the catatonia test using oral lorazepam eg® (n.v. eurogenerics s.a. brussels, belgium) using the 1 mg formulation tablets. it was proposed to perform a catatonia test using lorazepam (lzp) as first choice medication, as this is the medication that has been used most commonly in pediatric catatonia. the amount of drug given was based on the weight of the child. the lower dose (0.5 mg) was used as starting dose for patients with \ 30 kg body weight. a positive response to a catatonia test consisted of a reduction in catatonic symptoms, 30 or 60 minutes later, by at least 50% .positive responses were documented by video footage before and after administration of lzp. if no response to the initial dose of lzp, was observed after one hour, a second administration of the same medication at double the dose was given. catatonia was again assessed at 30 and 60 minutes thereafter. if no response was observed, the test was considered negative.

Eligibility criteria:
inclusion criteria: 1. children and adolescents with nodding syndrome as defined by the consensus definition agreed upon in the international nodding syndrome research meeting held in kampala, uganda july 2012. 2. presence of two or more catatonic items on the kampala catatonia panel. 3. written informed consent from caregiver. exclusion criteria: 1. children and adolescents with nodding syndrome who had a history of having used a benzodiazepine drug in the past 48 hours prior to intervention. 2. children and adolescents with nodding syndrome who had a concurrent acute illness (e.g febrile illness, pneumonia) at time of assessment.
odm 5 in the treatment of corneal edematous fuchs' endothelial dystrophy

Conditions: Fuchs' Endothelial Dystrophy; Corneal Edema

Summary: clinical observation to confirm the clinical safety and efficacy of odm 5 in the treatment of corneal edema caused by fuchs' endothelial dystrophy.

patients with a fuchs' endothelial dystrophy-induced corneal edema and an odm 5 therapy recommendation prior to their inclusion will be observed in normal practice setting in this post-market clinical follow-up study. in this indication, the use of odm 5 should extract the fluid excess in the cornea away by an osmotic effect, enabling the cornea to temporarily regain a normal state of hydration. as a consequence, the patient's visual acuity, contrast perception, corneal thickness and ocular complaints/symptoms should improve. the hyaluronan in odm 5 helps to protect and heal the cornea in case of irritation and thus, enables the cornea to regain a normal state of hydration and participates in improving the quality of vision.

Eligibility criteria:
inclusion criteria: * presence of corneal oedema caused by fuchs' endothelial dystrophy * existing odm 5 recommendation prior to inclusion exclusion criteria: * contact lens wear * hypersensitivity to one of the odm 5 components * appointment for eye surgery within 8 weeks after date of inclusion

Keywords: fuchs endothelial dystrophy oedema sodium chloride hyaluronan sodium hyaluronate
effect of beetroot juice on reducing hypertension in autosomal dominant polycystic kidney disease

Conditions: Autosomal Dominant Polycystic Kidney; Hypertension; Endothelial Dysfunction

Summary: people with autosomal dominant polycystic kidney disease (adpkd) develop high blood pressure and kidney disease. previous studies have shown that a commonly occurring chemical, nitric oxide (no), is reduced in adpkd, and may contribute, in part, to high blood pressure in this condition. nitrate is found in high concentrations naturally in beetroots, and increases no. the aim of this study is to determine if beetroot juice reduces blood pressure in hypertensive people with adpkd.


Eligibility criteria:
inclusion criteria: * diagnosis of autosomal dominant polycystic kidney disease * age \> 18 years old * estimated glomerular filtration rate (egfr) \> 30 ml/min/1.73m2 * treatment with at least one anti-hypertensive exclusion criteria: * inability to provide informed consent * labile, unstable, uncontrolled hypertension and/or changes in bp treatment 28 days prior to the screening visit * non-compliance with study procedures and/or daily bp measurements during the screening period * medical conditions or treatments that might interfere with the generation of no metabolites or the primary endpoint (e.g. nitrate drugs; cigarette smoking; unwilling to stop using antiseptic mouthwash; severe, uncontrolled hypercholesterolemia; pregnancy or post-partum and lactating) * any serious or other medical conditions that might interfere with follow-up or stability of blood pressure (e.g. current active malignancies; uncontrolled diabetes mellitus with elevated hba1c \> 10%) * dislike of taste of beetroot juice * allergy to beetroot * enrolled in other clinical trials

Keywords: autosomal dominant polycystic kidney disease adpkd beetroot juice hypertension nitrate supplementation nitric oxide
pro-permeability and pro-fibrosis factors in the aqueous of patients with retinal diseases

Conditions: Macular Edema; Fibrosis of the Retina

Summary: this study will examine potential factors in the aqueous humor that may contribute to the development or progression of macular edema or fibrosis (due to any underlying disease) in patients suffering from these conditions.

the primary purpose of this study is to determine the correlation of pro-permeability and pro-fibrosis factor levels and downstream receptor/signaling molecule activation with disease activity in patients with macular edema or fibrosis secondary to any underlying disease. 120 patients will be enrolled from both the clinic and or, with the latter patients undergoing surgery for proliferative diabetic retinopathy, rhegmatogenous retinal detachment with proliferative vitreoretinopathy (pvr), rhegmatogenous retinal detachment without pvr, macular pucker, or macular hole. clinic patients must be receiving an intraocular injection of a steroid as part of standard of care for macular edema or progressive fibrosis. surgical patients will receive an anterior chamber (ac) tap at the beginning of surgery, while clinic patients will receive an ac tap prior to the intraocular injection of steroid with a second ac tap at a follow-up visit 6 +/- 2 weeks after the first injection. the aqueous sample will then be analyzed by measuring the levels of various pro-permeability and pro-fibrosis factors and/or their downstream receptor/signaling molecule activation. we will also determine the correlation between reductions in foveal thickness or improvements in visual acuity with changes in the aqueous levels of pro-permeability and pro-fibrosis factors from baseline to week 6 in the clinic group.

Eligibility criteria:
inclusion criteria: * signed informed consent and authorization of use and disclosure of protected health information * age \>= 18 years * undergoing surgery as part of standard care for one of the following conditions: (1) proliferative diabetic retinopathy (pdr), (2) rhegmatogenous retinal detachment with pvr, (3) rhegmatogenous retinal detachment without pvr, (4) macular pucker, (5) macular hole or receiving as part of standard care, an intraocular injection of a steroid for macular edema or progressive fibrosis. exclusion criteria: * previous use of an anti-vascular endothelial growth factor (vegf) drug within 1 month of study entry * any condition that the investigator believes would pose a significant hazard to the subject if standard study procedures were conducted. * inability to comply with study or follow up procedures * patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. * pregnant patients.
assessment of peri-papillary retinal nerve fiber layer thickness in patients with unilateral branch retinal vein occlusion

Conditions: Branch Retinal Vein Occlusion

Summary: several studies have indicated a relation between the development of rvo and elevated intraocular pressure (iop) and glaucoma \[9\]. further investigations into the structural alterations in the fellow eyes of individuals with unilateral rvo have revealed that the prnfl is thinner than in healthy eyes, suggesting that there may be systemic risk factors for both rvo and glaucoma


Eligibility criteria:
inclusion criteria: * patients with unilateral brvo exclusion criteria: * history of retinal and/or optic nerve diseases involving glaucomatous optic disc, ischemic optic neuropathy, or optic neuritis. * history of trauma, intravitreal injections, vitreoretinal surgeries, and retinal or macular lasers. * a significant media opacity that makes it difficult to capture clear images. * no history of diabetes and/or hypertension in those recruited as the control group
acupuncture treatment for schizophrenia-related central obesity

Conditions: Schizophrenia; Central Obesity

Summary: this clinical trial aims to test the effect of acupuncture in patients with schizophrenia-related central obesity. the main question it aims to answer is: • the effect, safety, and maintenance of acupuncture on schizophrenia-related central obesity. participants will receive acupuncture treatment on purpose acupoints, acupuncture on acupoint peripheries, or fake acupuncture treatment on purpose acupoints for 20 weeks. and they need three follow-up visits during the treatment period and two follow-up visits after treatment. researchers will compare the waist circumstance of these three groups to see if the purpose acupoints are valid for schizophrenia-related central obesity.


Eligibility criteria:
inclusion criteria: * diagnosis with schizophrenia (diagnostic and statistical manual of mental disorders: fifth edition); * continuous use of antipsychotics for more than one year (may be combined with mood stabilizers, antianxiety medications, antidepressants, and benzodiazepines); * abdominal obesity (central obesity): waist circumference ≥90cm for men or ≥85cm for women (chinese standard); * all participants and their guardians signed informed consent. exclusion criteria: * had various traditional chinese medicine or chemical drugs, or acupuncture treatments for central obesity within two weeks before enrollment; * pregnant or lactating woman; * organic mental disorders and mental disorders induced by psychoactive and non-addictive substances; * with other diseases affecting their mental state (e.g., chronic obstructive pulmonary disease, coronary heart disease, angina pectoris, stroke, painful joint diseases, severe psychiatric diseases, tumors, and other physical diseases) * severe liver and kidney insufficiency or other serious diseases of the system; * with a family history of metabolic diseases such as hypertension, diabetes, and hyperlipidemia; * acupuncture dizziness, needle phobia, and other intolerant acupuncture treatment; * patients who are not treated according to the regulations, cannot determine the efficacy or have incomplete data affecting the efficacy and safety evaluation.